Engineered donor cells aim to beat blood cancer without severe side effects

This study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal is to see if this approach can prevent cancer relapse while reducing serious side effects like graft-versus-host disease. Participants also receive an extra infusion of memory T cells and, in some cases, a targeted drug called blinatumomab.